[The use of Lamiktal in treating epilepsy in children and adolescents].
Antiepileptic effects of lamiktal (lamotrigine) produced in Great Britain (Wellcome) was tried in 7 children aged 3-14 and 3 adults aged 18-30. Of them 6 patients and 4 patients suffered from temporal polymorphic fits and general paroxysms, respectively. Upon 3-month follow-up it was found that the fits discontinued in 4 patients, frequency of the paroxysms reduced or they became abortive in 6 cases. EEG changes were insignificant. No side effects occurred. Lamiktal is recommended in polymorphic seizures in children and adults, in failure of other anticonvulsants in patients frequently affected with epileptic paroxysms.
N N
NN
Solovykh
A G
AG
Korotkov
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects; D004832:Epilepsy, Absence / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy*; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D012074:Remission Induction; D014227:Triazines / Q000627:therapeutic use*
D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine
Primenenie lamiktala v lechenii épilepsii u deteĭ i podrostkov.